Phase 1 N=20 A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients
Cystic Fibrosis
Primary: Pharmacokinetic Assessment of a 5 Day Infusion of Gallium Nitrate (IV Ganite®) — 503; 537 ug*hr/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=15 Electro Flo 5000 and Vest Therapy
Cystic Fibrosis
Primary: Wet Sputum Weight — 3.8; 4.6 grams
Phase 2 N=40 Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children
Upper Respiratory Tract Infections
Primary: Respiratory Infectious Symptoms — 9; 13; 10; 13 days — p=>0.05
Phase 3 N=149 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
Aspergillosis · Invasive Fungal Infections
Primary: Crude Success Rate of Overall Outcome of Treatment Evaluated by the Data Review Committee (DRC) at Day 42, 84 and End of Treatment (EOT). — 25.0; 50.0; 14.3; 9.1…
Phase 2 N=314 Strategies To Prevent Pneumonia 2 (SToPP2)
Infections, Hospital · Ventilator-Associated Pneumonia · Mechanical Ventilation Complication
Primary: Development of VAP (Clinical Pulmonary Infection Score) — 4.13; 4.45 units on a scale — p=0.1763
N/A N=77 Education Effectiveness for Type 1 Diabetes Mellitus on Insulin Pump Therapy
Diabetes Mellitus, Type 1
Primary: HbA1c — 7.3; 8.0; 7.5; 8.8 percentage
Phase 3 N=163 A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
Seizure Disorder Generalized Tonic Clonic
Primary: Median Percent Change in Primary Generalized Tonic Clonic Seizure Frequency (PGTC) Per 28 Days During the Titration and Maintenance Periods (Combined) Relative to…
Phase 3 N=220 Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole
Vitreomacular Adhesion Including Macular Hole
Primary: Proportion of Subjects With Pharmacological Vitreomacular Adhesion (VMA) / (Vitreomacular Traction [VMT]) Resolution at Day 28 — 41.7; 6.2 Percentage (weighted across…
Phase 4 N=160 A Study of Bonviva (Ibandronate) Once Monthly in Post-Menopausal Women With Osteopenia
Post-Menopausal Osteopenia
Primary: Relative Change From Baseline in Mean Bone Mineral Density (BMD) of the Lumbar Spine (L2 to L4) at Month 12 — -0.3941; 3.7285 Percentage — p=<0.0001
Phase 3 N=20 Buprenorphine Maintenance Treatment of Opioid Dependence in Primary Care: A Randomized Clinical Trial
Opioid-Related Disorders · Heroin Dependence
Primary: The Primary Outcome Will Include a Comparison of the Proportion of Patients Successfully Inducted One Week After the Initial Primary Care Visit. — 6; 6 participants
N/A N=1,200 CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population
Colorectal Cancer · Adenomatous Polyp of Colon · Polyps
Primary: Ct Value (Ct Values From PCR Reaction) — 38.4; 44.3; 44.6 Ct
Phase 2 N=304 Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim
Breast Cancer
Primary: Maximum Patient-reported Bone Pain in Cycle 1 — 3.2; 3.5 units on a scale — p=0.3479
N/A N=77 Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System
Conductive Hearing Loss
Primary: Implant Stability — 66.7; 71.6; 67.4; 72.1 ISQ scores
Phase 2 N=96 Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
Alzheimer's Disease
Primary: Differences in ∆sCD40L Levels Between CHF 5074 Doses and Placebo at Any Specific Time Point — 270.28; 403.22; -1293.42; 242.49 pg/ml
Phase 1 N=36 A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
Colorectal Cancer
Primary: Area Under The Plasma Concentration-Time Curve From Zero To Infinity (AUC0-Inf) of 5'-Deoxy-5-fluorouridine 5'-(DFUR) — 13605; 12177; 11817 ng/mL*hr